National Guidelines for Stem Cell Research in India: A Complete Guide

Stem cell therapy is one of the most promising — and most misunderstood — frontiers in modern medicine. Over the past decade, India has seen a surge of clinics advertising “miracle” stem cell cures for everything from autism to spinal cord injury, often with little to no scientific backing. To protect patients and keep research ethical, the National Guidelines for Stem Cell Research (NGSCR) were created as India’s official regulatory framework governing how stem cells can be studied, banked, and used in treatment.

If you’re a patient exploring stem cell therapy, a researcher planning a study, or simply trying to understand what’s legal and what isn’t, this guide breaks down the National Guidelines for Stem Cell Research in plain language — including the regulatory bodies involved, what’s permitted versus prohibited, and the major updates through 2026, including a landmark Supreme Court ruling that reshaped the rules for stem cell therapy in India.

The National Guidelines for Stem Cell Research are a jointly issued framework from the Indian Council of Medical Research (ICMR) and the Department of Biotechnology (DBT), designed to govern the ethical, scientific, and clinical use of human stem cells in India.

Their evolution has happened in stages:

• 2007: The first “Guidelines for Stem Cell Research and Therapy” introduced a two-tier oversight system, implemented from 2010 onward.
• 2017: ICMR and DBT jointly released a comprehensively updated version — commonly referred to as the National Guidelines for Stem Cell Research, 2017 — in response to rapid scientific advances and a rise in unethical commercial stem cell clinics.
• 2023: Following expert and public consultations, the apex regulatory committee overseeing these guidelines was restructured, marking a significant shift in how stem cell research is governed nationally.
• 2025–2026: Updated advisories and clarifications followed, including a major Supreme Court judgment (discussed below) that directly affects how stem cell therapy can be offered in clinical practice.

At their core, the ICMR-DBT stem cell guidelines classify research and clinical use of stem cells as permissible, restricted, or prohibited, and they apply to every stakeholder — researchers, hospitals, sponsors, ethics committees, and commercial banks — involved in stem cell work in India.

The guidelines exist to balance scientific progress with patient protection. Their key objectives include:

• Patient safety — preventing patients from receiving unproven, potentially harmful stem cell interventions marketed as established treatments.
• Ethical research conduct — ensuring stem cell research, especially involving human embryonic stem cells, follows internationally aligned ethical standards.
• Curbing unproven and commercial exploitation — cracking down on clinics that offer stem cell “therapy” outside of approved clinical trials or standard-of-care indications.
• Scientific accountability — requiring registration, monitoring, and reporting from every institution conducting stem cell research or therapy.
• Building public trust — creating a transparent system so patients and the medical community can trust the legitimacy of stem cell treatments in India.

Several institutions work together to enforce the national guidelines for stem cell research and therapy:

Indian Council of Medical Research (ICMR)

The primary body responsible for drafting and updating stem cell research and ethical guidelines in India, in coordination with the DBT.

Department of Biotechnology (DBT)

Co-author of the guidelines and a key funder/promoter of legitimate stem cell research activities across Indian institutions.

Central Drugs Standard Control Organization (CDSCO)

The national drug regulatory authority responsible for approving stem cell clinical trials, particularly where stem cells undergo “more than minimal manipulation,” and for enforcing Good Manufacturing Practice (GMP) standards at research facilities.

National Apex Committee for Stem Cell Research and Therapy (NAC-SCRT)

Originally established as the top-level national oversight body for stem cell research, NAC-SCRT reviewed and monitored institutional compliance nationwide. In 2023, the Department of Health Research (DHR) and ICMR moved to dissolve this committee structure after citing implementation difficulties, marking a significant shift in India’s stem cell governance landscape. Oversight functions have since been redistributed, with bodies like the National Stem Cell Research Regulation Committee playing a coordinating role alongside DHR and CDSCO.

Institutional Committee for Stem Cell Research (IC-SCR)

The institution-level counterpart to the national committee, IC-SCR (formerly the Institutional Committee for Stem Cell Research and Therapy) reviews and monitors stem cell research proposals at the hospital or laboratory level, working alongside the Institutional Ethics Committee (IEC).

One of the most important features of the National Guidelines for Stem Cell Research is its three-tier classification system for research activities:

Permissible research includes most basic research using established stem cell lines, adult stem cells, umbilical cord stem cells, and induced pluripotent stem cells (iPSCs), provided it follows institutional review and ethical approval.

Restricted research covers more sensitive areas — such as certain uses of human embryonic stem cells (hESCs) — which require additional layers of scrutiny, including registration and oversight at both the institutional and (formerly) national committee level, given concerns around commoditization of human tissue and potential misuse.

Prohibited research includes activities banned outright under Indian law and the guidelines, such as reproductive cloning and germline genetic modification for reproductive purposes.

Understanding this tiered structure helps explain why not all “stem cell research” is treated equally — the level of oversight depends entirely on what kind of cells are used and how they’re manipulated.

The guidelines are especially strict when it comes to moving from research to actual patient treatment. Key requirements include:

• Mandatory clinical trial registration — any stem cell use in patients, beyond a small list of approved standard-of-care indications, is considered investigational and must occur within a registered, approved clinical trial.
• CDSCO and ethics committee approval — sponsors must secure clearance from CDSCO for trials involving significant cell manipulation, alongside sign-off from a registered Institutional Ethics Committee.
• GMP/GLP-certified facilities — clinical research and manufacturing of stem cell products must take place only at facilities certified under Good Manufacturing Practice (GMP) and Good Laboratory Practice (GLP) standards.
• Qualified investigators — research must be led by medical professionals with recognized postgraduate qualifications relevant to the specific trial domain.
• Informed consent and patient protection — trial participants must give written informed consent, cannot be charged for participating in a legitimate trial, and must be provided compensation provisions in case of trial-related injury.
• No therapy outside approved indications — currently, hematopoietic stem cell transplantation (HSCT) for specific, listed blood and immune disorders is the primary stem cell application approved as routine standard of care in India. Mesenchymal stem cell therapy, by contrast, is not currently approved as standard care for any condition and remains investigational.

Stem cell regulation in India has evolved significantly in the last few years:

NAC-SCRT restructuring (2023): As noted above, the dissolution of the original apex committee structure prompted a shift toward distributing oversight between DHR, CDSCO, and a newer National Stem Cell Research Regulation Committee.

The Yash Charitable Trust Supreme Court judgment (January 2026): In a landmark ruling on Yash Charitable Trust & Ors. v. Union of India & Ors. (W.P. (C) No. 369 of 2022), the Supreme Court of India held that stem cell therapy for Autism Spectrum Disorder (ASD) cannot be offered as a routine or commercial clinical treatment, citing insufficient scientific evidence. Importantly, the Court also affirmed that patient consent alone cannot legitimize the use of unproven stem cell treatments — a significant clarification of medical ethics in this space.

NMC-ICMR joint advisory (March 2026): Following the Supreme Court’s judgment, the National Medical Commission (NMC) and ICMR issued a formal advisory directing all medical colleges and institutions to comply strictly with the ruling. The advisory reiterated that any stem cell treatment falling outside the Ministry of Health and Family Welfare’s approved “standard care” list — or lacking proper CDSCO/DHR clearance — would be treated as illegal and subject to regulatory action.

Together, these developments have tightened enforcement considerably, closing loopholes that previously allowed some clinics to market unproven stem cell treatments as legitimate medical care.

If you or a loved one is considering stem cell therapy in India, understanding these regulations isn’t just academic — it can protect you from harm and financial loss.

• Treatment is either an approved standard-of-care indication (e.g., HSCT for a listed blood disorder) or delivered strictly within a registered, CDSCO/DHR-approved clinical trial
• The facility is GMP/GLP-certified
• You’re asked to give written informed consent and are clearly told about risks, alternatives, and the investigational nature of any non-standard treatment
• The treating institution has a registered Institutional Ethics Committee and IC-SCR

• Claims that stem cells can “cure” conditions with no approved indication (e.g., certain neurological, autoimmune, or developmental conditions) outside of a registered trial
• Pressure to pay large sums for treatment described as routine or guaranteed
• No mention of clinical trial registration, ethics committee approval, or regulatory oversight
• Vague or evasive answers about which regulatory body has approved the specific treatment

Choosing a provider that operates within the National Guidelines for Stem Cell Research isn’t just a legal formality — it’s a meaningful signal of medical accountability and patient safety.

The National Guidelines for Stem Cell Research exist to make sure that the promise of stem cell science translates into safe, ethical, evidence-based care — not exploitation. As India’s regulatory landscape continues to evolve, from the 2023 NAC-SCRT restructuring to the landmark 2026 Supreme Court ruling, staying informed is the best way to protect yourself or your loved ones when exploring treatment options.

If you’re considering stem cell therapy, always choose a provider that is transparent about regulatory approval, clinical trial status, and treatment evidence. Speak with our team to understand which stem cell treatments are currently approved for your condition, and how we ensure compliance with ICMR, DBT, and CDSCO regulations at every step.

This article is for informational purposes only and does not constitute medical or legal advice. Regulations referenced are subject to change; please consult official ICMR, DBT, CDSCO, and Supreme Court of India sources, or a qualified professional, for the most current requirements.